Drug Trial Radar · NCT06847724
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
183
Actual
Start
Jun 10, 2025
Primary completion
Nov 3, 2026
Study completion May 2027
Sponsor
- Lead sponsor
- SandozNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)? * Does have CYB704 the same treatment effect and side effects as the reference product? Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will: * Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU) * Visit the clinic for at least 15 treatment visits, checkups and tests * Will undergo regular magnetic resonance imaging (MRI) examinations
Conditions
- Relapsing Multiple Sclerosis
Interventions
CYB704Biological
Intravenous Infusion
Ocrevus-EUBiological
Intravenous Infusion
Ocrevus-USBiological
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration time curveTime frame: Week 1 - 3, week 3 - 25
Locations
41 sites in 8 countries. Site status is shown where the registry gives one.
Sandoz Investigational Site
Maitland, Florida
Sandoz Investigational Site
Ormond Beach, Florida
Sandoz Investigational Site
Banja Luka, Bosnia and Herzegovina
Sandoz Investigational Site
Bihać, Bosnia and Herzegovina
Sandoz Investigational Site 2
Sarajevo, Bosnia and Herzegovina
Sandoz Investigational Site
Sarajevo, Bosnia and Herzegovina
Sandoz Investigational Site
Pleven, Bulgaria
Sandoz Investigational Site 2
Plovdiv, Bulgaria
Sandoz Investigational Site
Plovdiv, Bulgaria
Sandoz Investigational Site 2
Sofia, Bulgaria
Sandoz Investigational Site 3
Sofia, Bulgaria
Sandoz Investigational Site 4
Sofia, Bulgaria
Sandoz Investigational Site 5
Sofia, Bulgaria
Sandoz Investigational Site
Sofia, Bulgaria
Sandoz Investigational Site
Varaždin, Croatia
Sandoz Investigational Site
Zagreb, Croatia
Sandoz Investigational Site
Rustavi, Georgia
Sandoz Investigational Site 2
Tbilisi, Georgia
Sandoz Investigational Site 3
Tbilisi, Georgia
Sandoz Investigational Site 4
Tbilisi, Georgia
Sandoz Investigational Site 5
Tbilisi, Georgia
Sandoz Investigational Site 6
Tbilisi, Georgia
Sandoz Investigational Site 7
Tbilisi, Georgia
Sandoz Investigational Site 8
Tbilisi, Georgia
Sandoz Investigational Site
Tbilisi, Georgia
Sandoz Investigational Site
Shtip, North Macedonia
Sandoz Investigational Site
Skopje, North Macedonia
Sandoz Investigational Site
Bydgoszcz, Poland
Sandoz Investigational Site 2
Katowice, Poland
Sandoz Investigational Site
Katowice, Poland
Sandoz Investigational Site
Lodz, Poland
Sandoz Investigational Site 2
Lublin, Poland
Sandoz Investigational Site
Lublin, Poland
Sandoz Investigational Site
Nowa Sól, Poland
Sandoz Investigational Site 2
Poznan, Poland
Sandoz Investigational Site
Poznan, Poland
Sandoz Investigational Site
Szczecin, Poland
Sandoz Investigational Site
Warsaw, Poland
Sandoz Investigational Site
Zabrze, Poland
Sandoz Investigational Site
Belgrade, Serbia
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.